Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ad35 vector vaccine for preventing SARS-CoV-2 infection

A vector vaccine, sars-cov-2 technology, applied in the field of Ad35 vector vaccine, can solve the problems of insufficient resistance to virus infection, low expression level, ineffective vaccine titer, etc., to achieve good safety, avoid replication, and improve safety Effect

Active Publication Date: 2021-01-15
GUANGZHOU N BIOMED LTD
View PDF1 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] However, experiments have shown that the natural SARS-CoV-2 spike protein S gene is expressed at a very low level in human kidney cells HEK293, so if the original S codon is used as an antigen, the vaccine may be ineffective or the potency is very low , insufficient resistance to viral infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ad35 vector vaccine for preventing SARS-CoV-2 infection
  • Ad35 vector vaccine for preventing SARS-CoV-2 infection
  • Ad35 vector vaccine for preventing SARS-CoV-2 infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0032] The amino acid sequence of the Spike protein (S) of SARS-CoV-2 is shown in YP_009724390.1, with a full length of 1273aa, denoted as NB1.

[0033] The pre-mRNA transcribed by eukaryotic cells can produce different mRNA splicing isoforms through different splicing methods (selecting different combinations of splicing sites), which ultimately leads to different proteins produced by the same gene sequence. This is very detrimental to protein expression. The inventor optimized the codon of the wild-type natural nucleic acid sequence and removed potential variable splicing sites based on his own technology, which ensured the uniqueness of protein expression and reduced the difficulty of subsequent protein purification. The optimized nucleic acid sequence is denoted as NB2, and its specific sequence is shown in SEQ ID NO: 1:

[0034]ATGTTCGTGTTTCTGGTGCTGCTGCCTCTGGTGAGCTCCCAGTGCGTGAACCTGACCACAAGGACCCAGCTGCCACCTGCCTATACCAATAGCTTCACACGGGGCGTGTACTATCCCGACAAGGTGTTTAGATCTAGCGTGCTGC...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an Ad35 vector vaccine for preventing SARS-CoV-2 infection. The Ad35 vector vaccine comprises an Ad35 vector loaded with a nucleic acid sequence as shown in SEQ ID NO: 1. Someembodiments of the invention have good safety and are convenient to use. Experiments show that the Ad35 vector vaccine can generate more S proteins in human cells. The Ad35 vector vaccine is expectedto be developed into a vaccine for preventing SARS-CoV-2 infection. Some examples of the invention can be used in combination with other vaccines, can also be used as a therapeutic vaccine for COVID-19, and can be inoculated at the initial stage of infection of a patient to quickly induce immune response in a human body so as to achieve a therapeutic effect.

Description

technical field [0001] The invention relates to an Ad35 vector vaccine for preventing SARS-CoV-2 infection. Background technique [0002] The novel coronavirus pneumonia epidemic is very serious and has spread to many countries around the world. As of March 6, 2020, there have been more than 100,000 confirmed cases of COVID-19 worldwide. However, for the new coronavirus, there are currently no specific antiviral drugs and preventive vaccines that have been clearly verified at home and abroad. Therefore, prevention and blocking the spread of the virus are the key to controlling the epidemic. Vaccines are the most cost-effective interventions to prevent and control 2019-nCoV infection. Published comparisons of more than 100 SARS-CoV-2 virus genomes show that the overall degree of mutation of the virus is low, and no recombination has occurred. Therefore, if the SARS-CoV-2 vaccine is successfully developed, it will be able to protect the population from the new coronavirus ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/215A61P31/14A61P11/00
CPCA61K39/12A61K2039/5256A61P11/00A61P31/14C12N2770/20034
Inventor 陈凌关素华杨臣臣汪乾
Owner GUANGZHOU N BIOMED LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com